Comparing Ingrezza to Austedo as treatments for Tardive Dyskinesia

Executed on:May 5, 2025 4:30 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: New York Medical College, SUNY

Clinical Professor of Psychiatry and Behavioral Sciences at NY Medical College, clinical professor of psychiatry at SUNY Upstate Medical University, and adjunct clinical professor of psychiatry, Icahn School of Medicine at Mount Sinai.
Currently a consultant in clinical trial design and interpretation frequent lecturer on the quantitative assessment of clinical trial results, including the metrics of number needed to treat and number needed to harm.
Main interests include schizophrenia, bipolar disorder, and major depressive disorder.

Interview Goal

This call will examine the current treatment landscape for tardive dyskinesia, highlighting existing therapies such as Austedo (Deutetrabenazine) and their limitations. We will also discuss the potential of INGREZZA (valbenazine) as a transformative option, focusing on its efficacy, safety profile, and role in addressing unmet needs.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.